DK3456344T3 - Proteiner, der er specifikke for baff og b7rp1, og anvendelser deraf - Google Patents

Proteiner, der er specifikke for baff og b7rp1, og anvendelser deraf Download PDF

Info

Publication number: DK3456344T3
Authority: DK; Denmark
Prior art keywords: b7rp1; baff; proteins specific; proteins; specific
Prior art date: 2013-03-13

Application number

DK18182864.1T

Other languages

English (en)

Inventor

Hailing Hsu

Ming Zhang

Gunasekaran Kannan

Frederick W Jacobsen

Wayne Tsuji

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-13

Filing date

2014-03-12

Publication date

2022-08-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50483540&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3456344(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-03-12 Application filed by Amgen Inc filed Critical Amgen Inc

2022-08-01 Application granted granted Critical

2022-08-01 Publication of DK3456344T3 publication Critical patent/DK3456344T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Mycology (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Orthopedic Medicine & Surgery (AREA)
Cell Biology (AREA)
Oncology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Saccharide Compounds (AREA)
Solid-Sorbent Or Filter-Aiding Compositions (AREA)

DK18182864.1T 2013-03-13 2014-03-12 Proteiner, der er specifikke for baff og b7rp1, og anvendelser deraf DK3456344T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361780260P	2013-03-13	2013-03-13
US201461942776P	2014-02-21	2014-02-21
EP14717310.8A EP2968491B1 (en)	2013-03-13	2014-03-12	Proteins specific for baff and b7rp1 and uses thereof

Publications (1)

Publication Number	Publication Date
DK3456344T3 true DK3456344T3 (da)	2022-08-01

Family

ID=50483540

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK14717310.8T DK2968491T3 (da)	2013-03-13	2014-03-12	BAFF- og B7RP1-specifikke proteiner og anvendelser deraf
DK18182864.1T DK3456344T3 (da)	2013-03-13	2014-03-12	Proteiner, der er specifikke for baff og b7rp1, og anvendelser deraf

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK14717310.8T DK2968491T3 (da)	2013-03-13	2014-03-12	BAFF- og B7RP1-specifikke proteiner og anvendelser deraf

Country Status (36)

Country	Link
US (3)	US10421823B2 (da)
EP (3)	EP3456344B1 (da)
JP (2)	JP6523243B2 (da)
KR (2)	KR102218723B1 (da)
CN (2)	CN105324127B (da)
AP (1)	AP2015008768A0 (da)
AU (1)	AU2014244498B2 (da)
CA (1)	CA2904992C (da)
CL (1)	CL2015002600A1 (da)
CR (1)	CR20150544A (da)
CY (2)	CY1120569T1 (da)
DK (2)	DK2968491T3 (da)
EA (1)	EA035388B1 (da)
ES (3)	ES2923909T3 (da)
HR (2)	HRP20181629T1 (da)
HU (2)	HUE040169T2 (da)
IL (1)	IL241281B (da)
JO (2)	JOP20140087B1 (da)
LT (2)	LT2968491T (da)
MX (2)	MX369502B (da)
MY (2)	MY171938A (da)
NZ (2)	NZ751502A (da)
PE (1)	PE20151772A1 (da)
PH (2)	PH12022550138A1 (da)
PL (2)	PL2968491T3 (da)
PT (2)	PT3456344T (da)
RS (2)	RS57689B1 (da)
SG (1)	SG11201507208VA (da)
SI (2)	SI3456344T1 (da)
SM (2)	SMT201800515T1 (da)
TN (1)	TN2015000414A1 (da)
TW (1)	TWI603978B (da)
UA (1)	UA120034C2 (da)
UY (1)	UY35396A (da)
WO (1)	WO2014159725A1 (da)
ZA (1)	ZA201506708B (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE549354T1 (de) *	2001-05-11	2012-03-15	Amgen Inc	Peptide und damit zusammenhängende an tall-1 bindende moleküle
PH12022550138A1 (en)	2013-03-13	2023-03-06	Amgen Inc	Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en) *	2013-03-13	2016-10-04	Amgen Inc.	Proteins specific for BAFF and B7RP1
ITUB20151014A1 (it)	2015-05-27	2016-11-27	Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro	Ligandi del recettore b7h nel trattamento di osteopenia e osteoporosi
CR20180365A (es)	2015-12-16	2018-09-28	Amgen Inc	PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
SG11202101922YA (en) *	2018-07-31	2021-03-30	Univ Tokyo	Highly versatile method for granting new binding specificity to antibody
CN111925442B (zh) *	2020-08-19	2022-10-11	重庆医科大学	新冠病毒rbd特异性单克隆抗体和应用
JP2026510999A (ja)	2023-03-21	2026-04-10	バイオグラフ５５，インク．	Ｃｄ１９／ｃｄ３８多重特異性抗体
WO2025125137A1 (en) *	2023-12-11	2025-06-19	Glaxosmithkline Intellectual Property Development Limited	Baff specific antibodies

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4263428A (en)	1978-03-24	1981-04-21	The Regents Of The University Of California	Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
DE3374837D1 (en)	1982-02-17	1988-01-21	Ciba Geigy Ag	Lipids in the aqueous phase
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
HUT35524A (en)	1983-08-02	1985-07-29	Hoechst Ag	Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en)	1983-11-01	1988-10-12	TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION	Pharmaceutical composition containing urokinase
US4496689A (en)	1983-12-27	1985-01-29	Miles Laboratories, Inc.	Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4740461A (en)	1983-12-27	1988-04-26	Genetics Institute, Inc.	Vectors and methods for transformation of eucaryotic cells
EP0154316B1 (en)	1984-03-06	1989-09-13	Takeda Chemical Industries, Ltd.	Chemically modified lymphokine and production thereof
US4959455A (en)	1986-07-14	1990-09-25	Genetics Institute, Inc.	Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5260203A (en)	1986-09-02	1993-11-09	Enzon, Inc.	Single polypeptide chain binding molecules
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
ATE87659T1 (de)	1986-09-02	1993-04-15	Enzon Lab Inc	Bindungsmolekuele mit einzelpolypeptidkette.
US4912040A (en)	1986-11-14	1990-03-27	Genetics Institute, Inc.	Eucaryotic expression system
US4970154A (en)	1987-10-09	1990-11-13	Baylor College Of Medicine	Method for inserting foreign genes into cells using pulsed radiofrequency
US4892538A (en)	1987-11-17	1990-01-09	Brown University Research Foundation	In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5106627A (en)	1987-11-17	1992-04-21	Brown University Research Foundation	Neurological therapy devices
US5158881A (en)	1987-11-17	1992-10-27	Brown University Research Foundation	Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US6018026A (en)	1988-01-22	2000-01-25	Zymogenetics, Inc.	Biologically active dimerized and multimerized polypeptide fusions
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5011472A (en)	1988-09-06	1991-04-30	Brown University Research Foundation	Implantable delivery system for biological factors
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
EP0401384B1 (en)	1988-12-22	1996-03-13	Kirin-Amgen, Inc.	Chemically modified granulocyte colony stimulating factor
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5225538A (en)	1989-02-23	1993-07-06	Genentech, Inc.	Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en)	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
JP2877509B2 (ja)	1989-05-19	1999-03-31	アムジエン・インコーポレーテツド	メタロプロテイナーゼ阻害剤
US5676954A (en)	1989-11-03	1997-10-14	Vanderbilt University	Method of in vivo delivery of functioning foreign genes
US6641809B1 (en)	1990-03-26	2003-11-04	Bristol-Myers Squibb Company	Method of regulating cellular processes mediated by B7 and CD28
US5151510A (en)	1990-04-20	1992-09-29	Applied Biosystems, Inc.	Method of synethesizing sulfurized oligonucleotide analogs
US5723286A (en)	1990-06-20	1998-03-03	Affymax Technologies N.V.	Peptide library and screening systems
ATE300615T1 (de)	1990-08-29	2005-08-15	Genpharm Int	Transgene mäuse fähig zur produktion heterologer antikörper
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5877397A (en)	1990-08-29	1999-03-02	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en)	1990-08-29	1999-02-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en)	1990-08-29	1998-08-04	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en)	1990-08-29	2001-10-09	Genpharm International	Transgenic non-human animals for producing heterologous antibodies
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US6565841B1 (en)	1991-03-15	2003-05-20	Amgen, Inc.	Pulmonary administration of granulocyte colony stimulating factor
JPH06508035A (ja)	1991-06-14	1994-09-14	ディーエヌエックス　コーポレーション	トランスジェニックブタにおけるヒトヘモグロビンの生産
US5270170A (en)	1991-10-16	1993-12-14	Affymax Technologies N.V.	Peptide library and screening method
US5733731A (en)	1991-10-16	1998-03-31	Affymax Technologies N.V.	Peptide library and screening method
CA2124967C (en)	1991-12-17	2008-04-08	Nils Lonberg	Transgenic non-human animals capable of producing heterologous antibodies
WO1993015722A1 (en)	1992-02-07	1993-08-19	Syntex (Usa) Inc.	Controlled delivery of pharmaceuticals from preformed porous microparticles
US5417972A (en)	1993-08-02	1995-05-23	The Board Of Trustees Of The Leland Stanford Junior University	Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
ATE218893T1 (de)	1993-08-12	2002-06-15	Neurotech Sa	Biokompatible immunoisolatorische kapseln, die genetisch veränderte zellen enthalten
US6268212B1 (en)	1993-10-18	2001-07-31	Amgen Inc.	Tissue specific transgene expression
US5625825A (en)	1993-10-21	1997-04-29	Lsi Logic Corporation	Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5922545A (en)	1993-10-29	1999-07-13	Affymax Technologies N.V.	In vitro peptide and antibody display libraries
US5484720A (en)	1994-09-08	1996-01-16	Genentech, Inc.	Methods for calcium phosphate transfection
DE4435919C1 (de)	1994-10-07	1995-12-07	Deutsches Krebsforsch	Zinkfinger-DNA, -Protein und ihre Verwendung
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
CA2222550A1 (en)	1995-06-07	1996-12-19	Baylor College Of Medicine	Nucleic acid transporters for delivery of nucleic acids into a cell
US6127977A (en)	1996-11-08	2000-10-03	Cohen; Nathan	Microstrip patch antenna with fractal structure
US5679559A (en)	1996-07-03	1997-10-21	University Of Utah Research Foundation	Cationic polymer and lipoprotein-containing system for gene delivery
EP0934526B1 (en)	1996-10-08	2003-01-08	U-BISys B.V.	Methods and means for selecting peptides and proteins having specific affinity for a target
ES2248823T5 (es)	1996-10-25	2011-11-03	Human Genome Sciences, Inc.	Neutroquina alfa.
US6812327B1 (en)	1996-10-25	2004-11-02	Human Genome Sciences, Inc.	Neutrokine-alpha polypeptides
WO1999035170A2 (en)	1998-01-05	1999-07-15	Genentech, Inc.	Compositions and methods for the treatment of tumor
EP1500329B1 (en)	1996-12-03	2012-03-21	Amgen Fremont Inc.	Human antibodies that specifically bind human TNF alpha
AU5705898A (en)	1996-12-17	1998-07-15	Schering Corporation	Mammalian cell surface antigens; related reagents
US7112655B1 (en)	1997-02-27	2006-09-26	Japan Tobacco, Inc.	JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (ja)	1997-02-27	2004-04-19	日本たばこ産業株式会社	細胞間接着及びシグナル伝達を媒介する細胞表面分子
US5969102A (en)	1997-03-03	1999-10-19	St. Jude Children's Research Hospital	Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
CA2232743A1 (en)	1997-04-02	1998-10-02	Smithkline Beecham Corporation	A tnf homologue, tl5
US20020062010A1 (en)	1997-05-02	2002-05-23	Genentech, Inc.	Method for making multispecific antibodies having heteromultimeric and common components
IL133315A0 (en)	1997-06-06	2001-04-30	Regeneron Pharma	Ntn-2 member of tnf ligand family
JP2002517977A (ja)	1997-06-06	2002-06-18	リジェネロンファーマシューティカルズ，インコーポレイテッド	Ｔｎｆリガンドファミリーのｎｔｎ−２メンバー
WO1999011791A2 (en)	1997-09-05	1999-03-11	University Of Washington	Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
CA2303424A1 (en)	1997-09-12	1999-03-18	Jurg Tschopp	Kay - a novel immune system protein
DE19821060A1 (de)	1997-09-23	1999-04-15	Bundesrepublik Deutschland Let	Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
US7259247B1 (en)	1997-09-23	2007-08-21	Bundersrespublik Deutschaland Letztvertreten Durch Den Direktor Des Robert-Koch-Institutes	Anti-human T-cell costimulating polypeptide monoclonal antibodies
WO1999062951A1 (en)	1998-06-04	1999-12-09	Shanghai Second Medical University	A human zinc finger protein gene (bmzf3)
US6660843B1 (en)	1998-10-23	2003-12-09	Amgen Inc.	Modified peptides as therapeutic agents
DE60043626D1 (de)	1999-01-07	2010-02-11	Zymogenetics Inc	Verfahren zur therapeutischen Verwendung von löslichen rezeptoren BR43X2
US20030095967A1 (en)	1999-01-25	2003-05-22	Mackay Fabienne	BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
BR0007719A (pt)	1999-01-25	2001-11-13	Biogen Inc	Baff, agentes de bloqueio relacionados e uso dosmesmos no estìmulo e na inibição de células b e deimunoglobulinas em respostas imunológicas
DK1149114T3 (da)	1999-02-03	2014-06-23	Amgen Inc	Polypeptider, der er involveret ved et immunrespons
US7708993B2 (en)	1999-02-03	2010-05-04	Amgen Inc.	Polypeptides involved in immune response
US8624010B1 (en)	1999-02-03	2014-01-07	Steven K. Yoshinaga	Nucleic acids encoding B7RP1
US7435796B1 (en)	1999-02-03	2008-10-14	Amgen Inc.	Antibodies which bind B7RP1
WO2000047740A2 (en)	1999-02-12	2000-08-17	Amgen Inc.	Tnf-related proteins
SI2168984T1 (sl)	1999-03-25	2012-12-31	Abbott Gmbh & Co. Kg	ÄŚloveĹˇka protitelesa za vezavo IL-12 in postopki izdelave
US20030022233A1 (en)	1999-04-30	2003-01-30	Raymond G. Goodwin	Methods of use of the taci/taci-l interaction
WO2000068378A1 (en)	1999-05-06	2000-11-16	National Jewish Medical And Research Center	Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
IL147270A0 (en)	1999-07-02	2002-08-14	Genentech Inc	Fusion peptides comprising a peptide ligand domain and a multimerization domain
DE60037896D1 (de)	1999-07-29	2008-03-13	Medarex Inc	Menschliche antikörper gegen her2/neu
AU6458400A (en)	1999-08-11	2001-03-13	Isis Innovation Limited	Nucleic acid, polypeptides, assays, therapeutic methods and means
IL148079A0 (en)	1999-08-24	2002-09-12	Medarex Inc	Human ctla-4 antibodies and compositions containing the same
JP4210454B2 (ja)	2001-03-27	2009-01-21	日本たばこ産業株式会社	炎症性腸疾患治療剤
JP3871503B2 (ja)	1999-08-30	2007-01-24	日本たばこ産業株式会社	免疫性疾患治療剤
EP1900816A3 (en)	1999-09-21	2008-03-26	Genetics Institute, LLC	GL50 molecules and uses therefor
PT1218504E (pt)	1999-09-21	2007-10-22	Genetics Inst Llc	Novas moléculas gl50 e suas utilizações
CA2400214A1 (en)	2000-02-11	2001-11-15	Amgen Inc.	Fusion receptor from tnf family
WO2001064704A1 (en)	2000-03-02	2001-09-07	Mayo Foundation For Medical Education And Research	hB7-H2, A NOVEL CO-STIMULATORY MOLECULE
AU2001268427B2 (en) *	2000-06-16	2007-03-29	Glaxosmithkline Intellectual Property Limited	Antibodies that immunospecifically bind to blys
US7879328B2 (en)	2000-06-16	2011-02-01	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to B lymphocyte stimulator
GB0016633D0 (en)	2000-07-07	2000-08-23	Bp Exploration Operating	Process
US6635750B1 (en)	2000-07-20	2003-10-21	Millennium Pharmaceuticals, Inc.	B7-H2 nucleic acids, members of the B7 family
CA2418006A1 (en)	2000-08-18	2002-02-28	Dyax Corp.	Binding polypeptides for b lymphocyte stimulator protein (blys)
WO2002016411A2 (en)	2000-08-18	2002-02-28	Human Genome Sciences, Inc.	Binding polypeptides and methods based thereon
AU1796902A (en)	2000-11-28	2002-06-11	Amgen Inc	Novel polypeptides involved in immune response
KR20030067755A (ko)	2001-01-18	2003-08-14	메르크 파텐트 게엠베하	글루코세레브로시다제 활성을 갖는 이관능성 융합 단백질
ATE549354T1 (de)	2001-05-11	2012-03-15	Amgen Inc	Peptide und damit zusammenhängende an tall-1 bindende moleküle
AR035119A1 (es)	2001-08-16	2004-04-14	Lilly Co Eli	Anticuerpos humanos antagonistas anti-htnfsf13b
WO2004043989A2 (en)	2002-11-07	2004-05-27	Medarex, Inc.	Human monoclonal antibodies to heparanase
CN100432105C (zh)	2002-12-17	2008-11-12	默克专利有限公司	与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
AU2003299971A1 (en)	2002-12-30	2004-07-29	Amgen Inc.	Combination therapy with co-stimulatory factors
SI1629011T1 (sl)	2003-05-31	2010-05-31	Micromet Ag	Humane molekule za vezavo anti hu cd
US7271245B2 (en)	2004-02-13	2007-09-18	The Scripps Research Institute	Methods and compositions for inhibition of metastasis
JPWO2006003999A1 (ja)	2004-07-05	2008-07-31	財団法人化学及血清療法研究所	ヒト抗ヒトｂ７ｒｐ−１抗体およびその抗体フラグメント
WO2006010057A2 (en)	2004-07-08	2006-01-26	Amgen Inc.	Therapeutic peptides
EA011879B1 (ru) *	2004-09-24	2009-06-30	Эмджин Инк.	МОЛЕКУЛЫ С МОДИФИЦИРОВАННЫМ Fc ФРАГМЕНТОМ
AU2006270009A1 (en)	2005-07-18	2007-01-25	Amgen Inc.	Human anti-B7RP1 neutralizing antibodies
KR20130108481A (ko) *	2005-08-19	2013-10-02	아보트 러보러터리즈	이원 가변 도메인 면역글로불린 및 이의 용도
AR056806A1 (es)	2005-11-14	2007-10-24	Amgen Inc	Moleculas quimericas de anticuerpo rankl- pth/ pthrp
JP5426531B2 (ja)	2007-03-27	2014-02-26	ザイモジェネティクス，インコーポレイテッド	自己免疫疾患の治療のためのＢＬｙＳ阻害および／またはＡＰＲＩＬ阻害ならびに免疫抑制剤の組み合わせ
US20090022720A1 (en)	2007-07-20	2009-01-22	Stephan Fischer	Conjugate of an antibody against CD4 and antifusogenic peptides
WO2009015345A1 (en) *	2007-07-25	2009-01-29	Amgen Inc.	Pharmaceutical compositions comprising fc fusion proteins
EP2200631A1 (en)	2007-10-16	2010-06-30	Zymogenetics, Inc.	Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
EP2072527A1 (en) *	2007-12-21	2009-06-24	Altonabiotec AG	Fusion polypeptides comprising a SHBG dimerization component and uses thereof
CA2711256C (en)	2008-01-03	2019-01-15	The Scripps Research Institute	Antibody targeting through a modular recognition domain
US8557243B2 (en)	2008-01-03	2013-10-15	The Scripps Research Institute	EFGR antibodies comprising modular recognition domains
ES2563027T3 (es)	2008-01-07	2016-03-10	Amgen Inc.	Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
FR2944448B1 (fr) *	2008-12-23	2012-01-13	Adocia	Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
EP2714738B1 (en)	2011-05-24	2018-10-10	Zyngenia, Inc.	Multivalent and monovalent multispecific complexes and their uses
AR090626A1 (es)	2012-04-20	2014-11-26	Lilly Co Eli	Anticuerpos anti-baff-anti-il-17 biespecificos
PH12022550138A1 (en)	2013-03-13	2023-03-06	Amgen Inc	Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en) *	2013-03-13	2016-10-04	Amgen Inc.	Proteins specific for BAFF and B7RP1
BR112015023752B1 (pt)	2013-03-15	2023-11-14	Zyngenia, Inc.	Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
WO2016039801A1 (en)	2014-01-31	2016-03-17	Boehringer Ingelheim International Gmbh	Novel anti-baff antibodies

2012
- 2012-03-12 PH PH1/2022/550138A patent/PH12022550138A1/en unknown
2014
- 2014-03-11 JO JOP/2014/0087A patent/JOP20140087B1/ar active
- 2014-03-12 RS RS20181088A patent/RS57689B1/sr unknown
- 2014-03-12 HU HUE14717310A patent/HUE040169T2/hu unknown
- 2014-03-12 MX MX2015012440A patent/MX369502B/es active IP Right Grant
- 2014-03-12 EA EA201591720A patent/EA035388B1/ru unknown
- 2014-03-12 RS RS20220711A patent/RS63431B1/sr unknown
- 2014-03-12 PL PL14717310T patent/PL2968491T3/pl unknown
- 2014-03-12 EP EP18182864.1A patent/EP3456344B1/en active Active
- 2014-03-12 HU HUE18182864A patent/HUE059507T2/hu unknown
- 2014-03-12 CN CN201480020434.6A patent/CN105324127B/zh active Active
- 2014-03-12 PE PE2015001973A patent/PE20151772A1/es unknown
- 2014-03-12 NZ NZ751502A patent/NZ751502A/en unknown
- 2014-03-12 UA UAA201508877A patent/UA120034C2/uk unknown
- 2014-03-12 DK DK14717310.8T patent/DK2968491T3/da active
- 2014-03-12 PT PT181828641T patent/PT3456344T/pt unknown
- 2014-03-12 US US14/776,399 patent/US10421823B2/en active Active
- 2014-03-12 SM SM20180515T patent/SMT201800515T1/it unknown
- 2014-03-12 ES ES18182864T patent/ES2923909T3/es active Active
- 2014-03-12 UY UY0001035396A patent/UY35396A/es active IP Right Grant
- 2014-03-12 EP EP20158997.5A patent/EP3689371B1/en active Active
- 2014-03-12 HR HRP20181629TT patent/HRP20181629T1/hr unknown
- 2014-03-12 NZ NZ711954A patent/NZ711954A/en unknown
- 2014-03-12 SM SM20220322T patent/SMT202200322T1/it unknown
- 2014-03-12 TW TW103108956A patent/TWI603978B/zh active
- 2014-03-12 EP EP14717310.8A patent/EP2968491B1/en active Active
- 2014-03-12 AU AU2014244498A patent/AU2014244498B2/en active Active
- 2014-03-12 ES ES14717310.8T patent/ES2687299T3/es active Active
- 2014-03-12 SI SI201431972T patent/SI3456344T1/sl unknown
- 2014-03-12 DK DK18182864.1T patent/DK3456344T3/da active
- 2014-03-12 JP JP2016501678A patent/JP6523243B2/ja active Active
- 2014-03-12 LT LTEP14717310.8T patent/LT2968491T/lt unknown
- 2014-03-12 CN CN201910521740.2A patent/CN110437336B/zh active Active
- 2014-03-12 PL PL18182864.1T patent/PL3456344T3/pl unknown
- 2014-03-12 KR KR1020157027042A patent/KR102218723B1/ko active Active
- 2014-03-12 MY MYPI2015703088A patent/MY171938A/en unknown
- 2014-03-12 MY MYPI2018002384A patent/MY198370A/en unknown
- 2014-03-12 HR HRP20220884TT patent/HRP20220884T1/hr unknown
- 2014-03-12 WO PCT/US2014/024908 patent/WO2014159725A1/en not_active Ceased
- 2014-03-12 LT LTEP18182864.1T patent/LT3456344T/lt unknown
- 2014-03-12 ES ES20158997T patent/ES3058850T3/es active Active
- 2014-03-12 AP AP2015008768A patent/AP2015008768A0/xx unknown
- 2014-03-12 KR KR1020217004604A patent/KR102361632B1/ko active Active
- 2014-03-12 SG SG11201507208VA patent/SG11201507208VA/en unknown
- 2014-03-12 SI SI201430908T patent/SI2968491T1/sl unknown
- 2014-03-12 CA CA2904992A patent/CA2904992C/en active Active
- 2014-03-12 PT PT14717310T patent/PT2968491T/pt unknown
2015
- 2015-09-07 IL IL241281A patent/IL241281B/en active IP Right Grant
- 2015-09-10 ZA ZA2015/06708A patent/ZA201506708B/en unknown
- 2015-09-11 MX MX2019013442A patent/MX2019013442A/es unknown
- 2015-09-11 PH PH12015502074A patent/PH12015502074A1/en unknown
- 2015-09-11 CL CL2015002600A patent/CL2015002600A1/es unknown
- 2015-09-11 TN TN2015000414A patent/TN2015000414A1/en unknown
- 2015-10-13 CR CR20150544A patent/CR20150544A/es unknown
2018
- 2018-08-09 CY CY20181100835T patent/CY1120569T1/el unknown
2019
- 2019-04-25 JP JP2019084291A patent/JP6825033B2/ja active Active
- 2019-09-23 US US16/579,321 patent/US11492417B2/en active Active
2021
- 2021-01-12 JO JOP/2021/0010A patent/JOP20210010A1/ar unknown
2022
- 2022-08-02 CY CY20221100527T patent/CY1125447T1/el unknown
- 2022-09-28 US US17/936,062 patent/US12479930B2/en active Active

Also Published As

Publication number	Publication date
PT2968491T (pt)	2018-11-08
BR112015022300A2 (pt)	2017-10-10
CN105324127B (zh)	2019-07-05
CY1120569T1 (el)	2019-07-10
PE20151772A1 (es)	2015-12-17
US20160024225A1 (en)	2016-01-28
JP2016512546A (ja)	2016-04-28
WO2014159725A1 (en)	2014-10-02
JP2019141084A (ja)	2019-08-29
PT3456344T (pt)	2022-07-29
UY35396A (es)	2014-09-30
EP2968491A1 (en)	2016-01-20
SI2968491T1 (sl)	2018-11-30
JP6523243B2 (ja)	2019-05-29
ES2923909T3 (es)	2022-10-03
SI3456344T1 (sl)	2022-09-30
CY1125447T1 (el)	2025-05-09
JP6825033B2 (ja)	2021-02-03
HUE059507T2 (hu)	2022-11-28
NZ711954A (en)	2021-07-30
KR102361632B1 (ko)	2022-02-14
US20210206881A1 (en)	2021-07-08
JOP20210010A1 (ar)	2023-01-30
KR20210021123A (ko)	2021-02-24
ZA201506708B (en)	2017-07-26
KR20150130343A (ko)	2015-11-23
AU2014244498A1 (en)	2015-09-24
MX2019013442A (es)	2020-01-14
BR112015022300A8 (pt)	2018-01-23
EP3456344A1 (en)	2019-03-20
PL2968491T3 (pl)	2019-01-31
CL2015002600A1 (es)	2016-09-09
MY198370A (en)	2023-08-28
HRP20220884T1 (hr)	2022-10-14
MY171938A (en)	2019-11-07
JOP20140087B1 (ar)	2021-08-17
PH12015502074A1 (en)	2016-01-25
EP3456344B1 (en)	2022-05-04
AP2015008768A0 (en)	2015-09-30
US10421823B2 (en)	2019-09-24
SG11201507208VA (en)	2015-10-29
HK1218885A1 (en)	2017-03-17
TW201446797A (zh)	2014-12-16
US12479930B2 (en)	2025-11-25
EP3689371A1 (en)	2020-08-05
EP3689371B1 (en)	2025-10-22
ES3058850T3 (en)	2026-03-13
NZ751502A (en)	2021-07-30
RS57689B1 (sr)	2018-11-30
HUE040169T2 (hu)	2019-02-28
IL241281A0 (en)	2015-11-30
DK2968491T3 (da)	2018-10-22
UA120034C2 (uk)	2019-09-25
CR20150544A (es)	2015-12-01
EA201591720A1 (ru)	2016-01-29
PL3456344T3 (pl)	2022-09-12
LT2968491T (lt)	2018-10-10
KR102218723B1 (ko)	2021-02-24
RS63431B1 (sr)	2022-08-31
CN105324127A (zh)	2016-02-10
TN2015000414A1 (en)	2017-01-03
US20230128444A1 (en)	2023-04-27
LT3456344T (lt)	2022-08-10
US11492417B2 (en)	2022-11-08
HRP20181629T1 (hr)	2018-12-14
MX2015012440A (es)	2016-01-25
CN110437336B (zh)	2024-08-27
CA2904992C (en)	2023-07-04
CN110437336A (zh)	2019-11-12
MX369502B (es)	2019-11-11
CA2904992A1 (en)	2014-10-02
AU2014244498B2 (en)	2017-12-14
EP2968491B1 (en)	2018-07-18
TWI603978B (zh)	2017-11-01
PH12022550138A1 (en)	2023-03-06
ES2687299T3 (es)	2018-10-24
SMT201800515T1 (it)	2018-11-09
SMT202200322T1 (it)	2022-11-18
EA035388B1 (ru)	2020-06-04
IL241281B (en)	2020-03-31

Publication	Publication Date	Title
DK3052485T3 (da)	2021-10-11	Heterocykliske forbindelser og anvendelser deraf
DK2968173T3 (da)	2020-12-21	Heterocykliske forbindelser og anvendelser deraf
DK3016946T3 (da)	2023-01-09	Substituerede benzofuranyl- og benzoxazolylforbindelser og anvendelser deraf
DK2968443T3 (da)	2021-12-06	Hepcidinanaloger og anvendelser deraf
CU20140003S4 (es)	2015-02-26	Frasco
DK3063144T3 (da)	2021-10-25	Antiparasitære og pesticid-isoxazolinforbindelser
DK3456344T3 (da)	2022-08-01	Proteiner, der er specifikke for baff og b7rp1, og anvendelser deraf
DK3030549T3 (da)	2019-05-13	Pyridazinonforbindelser og anvendelser deraf
EP2987858A4 (en)	2016-12-21	GENE MODIFIED COXSACKIE VIRUS
DK2952513T3 (da)	2019-09-02	Azolbenzenderivat
IL244370A0 (en)	2016-04-21	Short-term hashes
PL2945641T3 (pl)	2020-06-15	Cykloalkinowe pochodne sacharydów
DK3066089T3 (da)	2020-01-27	Substituerede n-acetyl-l-cysteinderivater og relaterede forbindelser
HRP20190133T1 (hr)	2019-03-22	Heterociklički spoj
BR302014000098S1 (pt)	2015-03-31	Configuração aplicada em suporte
DK3080385T3 (da)	2019-10-07	Forbedret lukkeapparat
EP2975687A4 (en)	2016-11-23	DUPLEXER
EP3009444A4 (en)	2016-11-30	ALPHA-oxoacyl-Amino-caprolactam derivative
TH1501003198A (th)	2016-12-02	สารประกอบเฮเทอโรไซคลิค
ES1079187Y (es)	2013-08-02	Babero perfeccionado
DE102013211500A8 (de)	2015-06-11	Abgasturbolader
TH1401006056B (th)	2016-05-10	เทอร์โบชาร์จเจอร์
UA28717S (uk)	2015-01-12	Гойдалка
FI10125U1 (fi)	2013-06-19	Keinu
ES1086729Y (es)	2013-11-06	Pulsera perfeccionada